Document Detail

Microfluidics and cancer: are we there yet?
MedLine Citation:
PMID:  23358873     Owner:  NLM     Status:  MEDLINE    
More than two decades ago, microfluidics began to show its impact in biological research. Since then, the field of microfluidics has evolving rapidly. Cancer is one of the leading causes of death worldwide. Microfluidics holds great promise in cancer diagnosis and also serves as an emerging tool for understanding cancer biology. Microfluidics can be valuable for cancer investigation due to its high sensitivity, high throughput, less material-consumption, low cost, and enhanced spatio-temporal control. The physical laws on microscale offer an advantage enabling the control of physics, biology, chemistry and physiology at cellular level. Furthermore, microfluidic based platforms are portable and can be easily designed for point-of-care diagnostics. Developing and applying the state of the art microfluidic technologies to address the unmet challenges in cancer can expand the horizons of not only fundamental biology but also the management of disease and patient care. Despite the various microfluidic technologies available in the field, few have been tested clinically, which can be attributed to the various challenges existing in bridging the gap between the emerging technology and real world applications. We present a review of role of microfluidics in cancer research, including the history, recent advances and future directions to explore where the field stand currently in addressing complex clinical challenges and future of it. This review identifies four critical areas in cancer research, in which microfluidics can change the current paradigm. These include cancer cell isolation, molecular diagnostics, tumor biology and high-throughput screening for therapeutics. In addition, some of our lab's current research is presented in the corresponding sections.
Zhuo Zhang; Sunitha Nagrath
Related Documents :
24406433 - Reconciliation of classification systems defining molecular subtypes of colorectal canc...
24886523 - Muc16 (ca125): tumor biomarker to cancer therapy, a work in progress.
21860513 - N-nitrosamines (15 listings): n-nitrosomorpholine.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review    
Journal Detail:
Title:  Biomedical microdevices     Volume:  15     ISSN:  1572-8781     ISO Abbreviation:  Biomed Microdevices     Publication Date:  2013 Aug 
Date Detail:
Created Date:  2013-07-16     Completed Date:  2014-04-21     Revised Date:  2014-08-04    
Medline Journal Info:
Nlm Unique ID:  100887374     Medline TA:  Biomed Microdevices     Country:  United States    
Other Details:
Languages:  eng     Pagination:  595-609     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cell Separation
Drug Screening Assays, Antitumor
Microfluidic Analytical Techniques / methods*
Molecular Diagnostic Techniques
Neoplasms* / diagnosis,  drug therapy,  metabolism,  pathology
Neoplastic Cells, Circulating / pathology
Grant Support
1DP2 OD006672-01/OD/NIH HHS; DP2 OD006672/OD/NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The HECTD3 E3 Ubiquitin Ligase Suppresses Cisplatin-Induced Apoptosis via Stabilizing MALT1.
Next Document:  Characterization of cell seeding and specific capture of B cells in microbubble well arrays.